Kolexia
Jacot William Oncologie médicale
Jacot William
Oncologie médicale
Icm Montpellier
Montpellier, France
345 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs du sein Métastase tumorale Tumeurs du sein triple-négatives Tumeurs du cerveau Cellules tumorales circulantes Récidive tumorale locale Tumeur du sein de l'homme Carcinomes Carence en vitamine D

Collaborateurs

Voir plus
Dalenc Florence
Dalenc Florence
Institut Universitaire du Cancer Toulouse Oncopole, Toulouse, France
Bachelot Thomas
Bachelot Thomas
Centre Léon-Bérard, Lyon, France
Ferrero Jean Marc
Ferrero Jean Marc
Centre Antoine Lacassagne, Nice, France
Romieu Gilles
Romieu Gilles
Institut régional du cancer de Montpellier, Lieu inconnu

Industries

Voir plus
AstraZeneca
43 collaboration(s)
Dernière en 2023
Novartis
42 collaboration(s)
Dernière en 2023
Daiichi Sankyo
26 collaboration(s)
Dernière en 2023
Seagen
13 collaboration(s)
Dernière en 2023

Dernières activités

Voir plus
HER2CLIMB-05: A Randomized, Double-blind, Phase 3 Study of Tucatinib or Placebo in Combination With Trastuzumab and Pertuzumab as Maintenance Therapy for Metastatic HER2+ Breast Cancer (HER2CLIMB-05)
Essai Clinique (Seagen)   15 mars 2024
CUPCAKE: Early Detection of Triple Negative Breast Cancer Relapse: a Clinical Utility Phase II Trial
Essai Clinique (Institut Curie)   06 mars 2024
REPARP: Prospective and Multicentric Study Evaluating DNA Double-strand Breaks (DSBs) REpair Factors (POLQ, Shieldin Complex and 53BP1) Expression as Biomarker of PARP Inhibitor Resistance in Patients With Deleterious Germline Mutation in BRCA 1/2 and HER2-negative, Metastatic or Locally Advanced Breast Cancer.
Essai Clinique (Artios Pharma Ltd)   26 février 2024
A Study of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy in Patients With HER2-Positive Breast Cancer Who Have Residual Tumor in the Breast or Axillary Lymph Nodes Following Preoperative Therapy (KATHERINE): A Randomized, Multicenter, Open-Label Phase III Study to Evaluate the Efficacy and Safety of Trastuzumab Emtansine Versus Trastuzumab as Adjuvant Therapy for Patients With HER2-Positive Primary Breast Cancer Who Have Residual Tumor Present Pathologically in the Breast or Axillary Lymph Nodes Following Preoperative Therapy
Essai Clinique (Roche)   05 février 2024
ALCINA: Analysis of Circulating Tumor Markers in the Blood
Essai Clinique (Institut Curie)   01 février 2024
DS-8201a Versus T-DM1 for Human Epidermal Growth Factor Receptor 2 (HER2)-Positive, Unresectable and/or Metastatic Breast Cancer Previously Treated With Trastuzumab and Taxane [DESTINY-Breast03]: A Phase 3, Multicenter, Randomized, Open-Label, Active-Controlled Study of DS-8201a (Trastuzumab Deruxtecan), an Anti-HER2 Antibody Drug Conjugate (ADC), Versus Ado Trastuzumab Emtansine (T-DM1) for HER2-Positive, Unresectable and/or Metastatic Breast Cancer Subjects Previously Treated With Trastuzumab and Taxane
Essai Clinique (Daiichi Sankyo)   17 janvier 2024
Efficacy of a physiotherapy, yoga and patient education programme for patients with breast cancer and hormone therapy-induced pain: a multicentre randomised study protocol (SKYPE 2).
BMJ open   08 janvier 2024
First evidence of AXL expression on circulating tumor cells in metastatic breast cancer patients: A proof-of-concept study.
Cancer medicine   22 décembre 2023
SAFIR 03: A ctDNA Screening Program in Patients With HR+, HER2- Metastatic Breast Cancer for Detection of High-risk Relapse Patients on Any CDK4/6 Inhibitor and a Randomised Phase II Study Comparing Alpelisib Combined With Fulvestrant to Ribociclib Combined With Fulvestrant, in Patients With Persistent Targetable PIK3CA Mutations
Essai Clinique (Unicancer)   20 novembre 2023
Circulating tumour cells and PD-L1-positive small extracellular vesicles: the liquid biopsy combination for prognostic information in patients with metastatic non-small cell lung cancer.
British journal of cancer   16 novembre 2023